Evidence map›Paper›PMID 34586367›Full record

ArticleJAMA network open2021

Symptoms and Health Outcomes Among Survivors of COVID-19 Infection 1 Year After Discharge From Hospitals in Wuhan, China.

Xue Zhang, Fang Wang, Ye Shen, Xiaohua Zhang, Yuan Cen, Bin Wang, Songtao Zhao, Yi Zhou, Baoman Hu, Man Wang and 8 more

Abstract read
In one paragraph

Article in JAMA network open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 134 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
134citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

134 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. SARS-CoV-2 post-acute sequelae in previously hospitalised patients: systematic literature review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2023
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Prevalence, risk factors and treatments for post-COVID-19 breathlessness: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2022
    Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

74 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Xue ZhangDepartment of Respiratory Medicine, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Fang WangDepartment of Respiratory Medicine, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Ye ShenDepartment of Respiratory Medicine, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Xiaohua ZhangDepartment of General Surgery, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Yuan CenWuhan Huoshenshan Hospital, Wuhan, China.
Bin WangWuhan Huoshenshan Hospital, Wuhan, China.
Songtao ZhaoWuhan Huoshenshan Hospital, Wuhan, China.
Yi ZhouWuhan Huoshenshan Hospital, Wuhan, China.
Baoman HuDepartment of Respiratory Medicine, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Man WangDepartment of Respiratory Medicine, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Yuhui LiuDepartment of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Hongming MiaoDepartment of Biochemistry and Molecular Biology, Third Military Medical University (Army Medical University), Chongqing, China.
Paul JonesInstitute of Infection and Immunology, University of London, London, United Kingdom.
Xiangyu MaDepartment of Epidemiology, College of Preventive Medicine, Third Military Medical University (Army Medical University), Chongqing, China.
Yong HeDepartment of Respiratory Medicine, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Guoqiang CaoDepartment of Respiratory Medicine, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Lixia ChengDepartment of Medical and Research Management, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Li LiDepartment of Respiratory Medicine, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: The long-term health outcomes and symptom burden of COVID-19 remain largely unclear. Objective: To evaluate health outcomes of COVID-19 survivors 1 year after hospital discharge and to identify associated risk factors. Design, Setting, and Participants: This retrospective, multicenter cohort study was conducted at 2 designated hospitals, Huoshenshan Hospital and Taikang Tongji Hospital, both in Wuhan, China. All adult patients with COVID-19 discharged between February 12 and April 10, 2020, were screened for eligibility. Of a consecutive sample of 3988 discharged patients, 1555 were excluded (796 declined to participate and 759 were unable to be contacted) and the remaining 2433 patients were enrolled. All patients were interviewed via telephone from March 1 to March 20, 2021. Statistical analysis was performed from March 28 to April 18, 2021. Exposures: COVID-19. Main Outcomes and Measures: All patients participated in telephone interviews using a series of questionnaires for evaluation of symptoms, along with a chronic obstructive pulmonary disease (COPD) assessment test (CAT). Logistic regression models were used to evaluate risk factors for fatigue, dyspnea, symptom burden, or higher CAT scores. Results: Of 2433 patients at 1-year follow-up, 1205 (49.5%) were men and 680 (27.9%) were categorized into the severe disease group as defined by the World Health Organization guideline; the median (IQR) age was 60.0 (49.0-68.0) years. In total, 1095 patients (45.0%) reported at least 1 symptom. The most common symptoms included fatigue, sweating, chest tightness, anxiety, and myalgia. Older age (odds ratio [OR], 1.02; 95% CI, 1.01-1.02; P < .001), female sex (OR, 1.27; 95% CI, 1.06-1.52; P = .008), and severe disease during hospital stay (OR, 1.43; 95% CI, 1.18-1.74; P < .001) were associated with higher risks of fatigue. Older age (OR, 1.02; 95% CI, 1.01-1.03; P < .001) and severe disease (OR, 1.51; 95% CI, 1.14-1.99; P = .004) were associated with higher risks of having at least 3 symptoms. The median (IQR) CAT score was 2 (0-4), and a total of 161 patients (6.6%) had a CAT score of at least 10. Severe disease (OR, 1.84; 95% CI, 1.31-2.58; P < .001) and coexisting cerebrovascular diseases (OR, 1.95; 95% CI, 1.07-3.54; P = .03) were independent risk factors for CAT scores of at least 10. Conclusions and Relevance: This study found that patients with COVID-19 with severe disease during hospitalization had more postinfection symptoms and higher CAT scores.

Indexed as

HospitalsPatient DischargeSeverity of Illness IndexSurvivorsAgedAnxietyChinaCitiesCOVID-19DyspneaFatigueFemaleHospitalizationHumansLogistic ModelsMale

Identifiers

PMID34586367
PMCPMC8482055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.